Drug search by name

Decitabine Intravenous and Hematological toxicity

Result of checking the interaction of drug Decitabine Intravenous and disease Hematological toxicity for safety when used together.

Check result:

Decitabine Intravenous <> Hematological toxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Treatment with decitabine is associated with neutropenia and thrombocytopenia. It is recommended to consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with myelodysplastic syndromes (MDS). Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, before each dosing cycle. After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted according to manufacturer recommendations. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS. Closely monitor patients at risk for hematological toxicities.

Decitabine Intravenous

Generic Name: decitabine

Brand Name: Dacogen

Synonyms: Decitabine

What is Decitabine Intravenous?